BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020)

BridgeBio Pharma (BBIO) reported Non-Current Deferred Tax Liability of $1.1 million for Q4 2020.

BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020) Analysis & Trends

BridgeBio Pharma (BBIO) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $1.1 million in Q4 2020.

For the quarter ending Q4 2020, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2020 stood at $1.1 million (changed N/A YoY), and the FY2020 full-year result was $1.1 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability held at $1.1 million in Q4 2020.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2020 to a low of $1.1 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn

Download Data

Date	Value
Dec 31, 2020	1.10 Mn
Dec 31, 2020	1.10 Mn